metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus ipilimumab alone
	pembrolizumab (10mg/kg) vs. ipilimumab alone	1
	pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone	1
versus Standard of Care (SoC)
	nivolumab alone vs. Standard of Care (SoC)	1
	pembrolizumab (10mg/kg) vs. Standard of Care (SoC)	1
	pembrolizumab (2mg/kg) vs. Standard of Care (SoC)	1